ATHENEX INC’s (NASDAQ:ATNX) quiet period will expire on Monday, July 24th. ATHENEX INC had issued 6,000,000 shares in its IPO on June 14th. The total size of the offering was $66,000,000 based on an initial share price of $11.00. During ATHENEX INC’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Separately, Deutsche Bank AG started coverage on shares of ATHENEX INC in a research report on Monday, July 10th. They set a “buy” rating and a $20.00 price target on the stock.
COPYRIGHT VIOLATION WARNING: This report was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/08/athenex-incs-quiet-period-will-expire-on-july-24th-nasdaqatnx-updated-updated.html.
ATHENEX INC (NASDAQ ATNX) opened at 14.21 on Tuesday. The stock’s 50 day moving average is $16.86 and its 200 day moving average is $16.86. The firm’s market cap is $578.15 million. ATHENEX INC has a one year low of $11.21 and a one year high of $20.79.
In other news, Director Song-Yi Zhang bought 328,637 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was purchased at an average cost of $11.00 per share, with a total value of $3,615,007.00. Following the acquisition, the director now directly owns 4,000 shares in the company, valued at $44,000. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Johnson Yiu Nam Lau bought 25,200 shares of the business’s stock in a transaction dated Monday, June 19th. The shares were purchased at an average cost of $11.00 per share, with a total value of $277,200.00. Following the completion of the acquisition, the chief executive officer now owns 2,722,722 shares in the company, valued at $29,949,942. The disclosure for this purchase can be found here.
A hedge fund recently bought a new stake in ATHENEX INC stock. Bank of New York Mellon Corp purchased a new position in shares of ATHENEX INC (NASDAQ:ATNX) during the second quarter, according to its most recent filing with the SEC. The firm purchased 15,000 shares of the company’s stock, valued at approximately $240,000. Institutional investors own 0.12% of the company’s stock.
About ATHENEX INC
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for ATHENEX INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATHENEX INC and related companies with MarketBeat.com's FREE daily email newsletter.
